AusperBio Raises $120M for AHB-137 Phase 3

AusperBio completed enrollment in a 577-person Phase 3 trial before announcing the $120M Series C meant to carry its lead chronic hepatitis B program toward potential commercialization. The financing was announced on August 27, 2026, and was led by an unnamed strategic investor. RA Capital Management participated as a new investor, while HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments returned.

The sequence explains why the round matters. Early-stage biotechnology capital pays to establish whether a scientific idea can become a clinical program. AusperBio is raising late-stage capital after AHB-137 has moved into a registrational study, which means the company must fund clinical execution, regulatory preparation, manufacturing and commercial readiness at the same time. It is also advancing AHB-171, a second investigational chronic hepatitis B candidate built on a different RNA-directed platform.

Both programs are aimed at a persistent gap in hepatitis B treatment. Existing therapies can suppress viral replication, but functional cure remains uncommon. The World Health Organization estimates that 254M people were living with hepatitis B in 2022 and that the disease caused 1.1M deaths that year, mainly through cirrhosis and liver cancer.

What Happened

The official Series C announcement says an unnamed strategic investor led the $120M financing. RA Capital joined the cap table as a new investor, with six existing investors continuing their support. AusperBio did not disclose a valuation, ownership terms, or the identity of the strategic lead.

AusperBio says the Series C brings its capital raised since 2024 to $360M. The named public rounds reviewed by DevCuration total $343M: a $37M Series A, $73M Series B, $50M Series B+, $63M Series B2, and the new $120M Series C. The $17M difference is not explained by the announcement history reviewed, so the cumulative figure should be treated as company-reported rather than independently reconciled.

The company plans to use the financing to advance AHB-137 through its Phase 3 registrational program and prepare for potential commercialization. Capital will also support AHB-171, next-generation combination approaches for chronic hepatitis B, and a broader pipeline of targeted oligonucleotide therapeutics.

AHB-137 Has Reached the Late-Stage Handoff

AHB-137 is an investigational unconjugated antisense oligonucleotide developed through AusperBio's Med-Oligo platform. The company says it is designed to suppress production of hepatitis B surface antigen, inhibit viral DNA replication, and promote immune reactivation. Those mechanisms describe the therapeutic goal, not a proven commercial outcome; AHB-137 has not been approved by any regulatory authority.

The ClinicalTrials.gov record for AUSHINE lists the Phase 3 study as active and no longer recruiting. It enrolled 577 participants across 28 sites in China and is evaluating AHB-137 in HBeAg-negative chronic hepatitis B patients receiving nucleos(t)ide analogue therapy. The registry estimates primary completion on December 18, 2026, and study completion on October 31, 2027.

That timeline changes the job of the financing. AusperBio is no longer funding only the movement of a candidate into humans. The company must keep a large registrational study moving while building the regulatory, manufacturing, and commercial capabilities it may need if the data support approval. A related DevCuration story about Oak Hill Bio's pivotal antisense program shows the same capital pressure from a different direction: late-stage oligonucleotide programs require execution across science, operations, and regulatory strategy at once.

Why AHB-171 Changes the Financing Story

AusperBio is not using the Series C only to carry one candidate toward a readout. AHB-171 is an investigational hepatocyte-targeted small interfering RNA candidate built on the company's Au-HALO liver-targeting delivery platform. The company announced first patient dosing on August 3, 2026, making it AusperBio's second clinical-stage therapeutic candidate.

The two programs give AusperBio different ways to attack the same disease biology. AHB-137 is an antisense oligonucleotide; AHB-171 is an siRNA candidate. The financing also supports combination approaches, which matters because a functional cure may require multiple biological effects rather than one mechanism carrying the entire burden.

This strategy is still an investigational portfolio, not evidence of eventual approval. The distinction is central to late-stage biotech. A company can have an active Phase 3 program, a second clinical candidate, and a deep investor syndicate while biology, trial design, regulators, manufacturing, and adoption retain the power to change the outcome.

The Investor Signal

The Series C pairs an unnamed strategic lead with specialist healthcare investor RA Capital and a returning cross-border syndicate. That structure suggests investors are underwriting both the maturity of AHB-137 and the option value of a broader chronic hepatitis B platform. The continuing participation from HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments also gives the company continuity across its United States and China operations.

The financing arrives in a market where late-stage biotechnology rounds are being tied closely to specific clinical and commercial transitions. Rejoni's funding for regulatory and commercial readiness and NewLimit's Series C ahead of human trials sit at different points on that curve. AusperBio is farther along clinically than many venture-backed platform companies, but the capital burden grows as the company approaches decisions that can no longer be answered by preclinical promise.

What This Signals

AusperBio's $120M Series C is a wager on coordinated execution. Guofeng Cheng, co-founder and CEO, and Chris Yang, co-founder and CSO, must carry a fully enrolled Phase 3 study toward its primary endpoint while preparing the organization for regulatory review and potential commercialization. At the same time, the team is advancing AHB-171 and combination strategies that could determine whether AusperBio becomes a single-asset company or a broader chronic hepatitis B platform.

The round gives the company more time and operating capacity, but it does not move the scientific finish line. AHB-137's registrational evidence remains ahead, AHB-171 is earlier in development, and the strategic lead investor remains undisclosed. The next decisive movement will come from the clinical record and the infrastructure AusperBio builds around it while those results mature.